Cargando…

octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klukowska, Anna, Komrska, Vladimír, Vdovin, Vladimír, Zozulya, Nadezhda, Lissitchkov, Toshko, Oldenburg, Johannes, Ettingshausen, Carmen Escuriola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171997/ https://www.ncbi.nlm.nih.gov/pubmed/32341775 http://dx.doi.org/10.1177/2040620720914692

Ejemplares similares

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
por: Lissitchkov, Toshko, et al.
Publicado: (2019)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023)

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
por: Liesner, Ri J., et al.
Publicado: (2021)

Haemophilia - diagnosis and management challenges
por: Shetty, Shrimati
Publicado: (2014)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Lowering water's octane.
Publicado: (1998)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors
por: Brackmann, Hans H., et al.
Publicado: (2020)

Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers
por: Blamey, Greig, et al.
Publicado: (2021)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

Cardiovascular disease in hereditary haemophilia: The challenges of longevity
por: Shapiro, Susan, et al.
Publicado: (2022)

Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
por: Batorova, Angelika, et al.
Publicado: (2022)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

Spontaneous Spinal Epidural Haematoma Secondary to Autoimmune Acquired Haemophilia
por: Afshari, Fardad T., et al.
Publicado: (2018)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
por: Martinowitz, U, et al.
Publicado: (2015)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Octane-1,8-diyldipyridinium dibromide dihydrate
por: Xiao, Xin, et al.
Publicado: (2007)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

The Treatment of Haemophilia
por: Biggs, Rosemary
Publicado: (1969)

Living with Haemophilia
por: Laffan, Mike
Publicado: (1995)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Total Hip Replacement in Severe Haemophilia A: Challenges and Feasibility
por: Bhattacharjee, Sujoy K, et al.
Publicado: (2022)

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
por: Pulanić, Dražen, et al.
Publicado: (2023)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tdilkvj033vtgn0b7bl335ulhh